Lassa virus, also known as the Lassa mammarenavirus (LASV), is the arenavirus known to cause Lassa hemorrhagic fever in humans and other primates. Lassa virus requires biosafety level-equivalent containments. It is an endemic in many West African countries such as the Republic of Guinea, Liberia, Nigeria, and Sierra Leona, where the annual number of Lassa viral fever cases is between 300,000 and 500,000, resulting in the annual death of 5,000 infected patients. The spread of the disease is linked to the village of Lassa in Nigeria where a missionary nurse first contracted it in 1969. In humans, the Lassa virus is spread through contact with infected Mastomyl natalensis, the multimammate rat.
COVID-19 Impact Analysis
- COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
- Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.
- However, with COVID-19, the supply chain of the raw materials required to manufacture drugs for the Lassa virus has been disrupted in many countries. In addition, the market growth of pharmaceuticals is declining as the manufacturers of drugs have slowed down their production because of the pandemic. This, in turn, is expected to have a significant impact on the Lassa virus market.
Top Impacting Factors
Rising prevalence of Lassa fever in many developing economies and low-income countries is fuelling the growth of the Lassa virus market.
Growing population of Mastomys rats all over the world is another factor contributing to the growth of the Lassa virus market. Humans often become infected with the Lassa virus when they come in contact with the feces or urine of infected Mastomys rats.
Lassa virus is commonly widespread in some areas of Sierra Leone and Liberia; however, international travels from such regions to all corners of the world have increased the chances of the spreading of the virus. This factor is further contributing to the growth of the Lassa virus market.
However, the difficulty to diagnose the Lassa virus based on a patient's clinical presentation and the dearth of skilled healthcare professionals in low-income countries are some of the factors that are impeding the growth of the Lassa virus market.
Key Market Trends
- The global Lassa virus market is expected to witness a boost during the forecast period especially in the region of West Africa, owing to the emergence of 100,000 to 300,000 cases of Lassa fever each year.
- According to the World Health Organization (WHO), around 10–15% of people who have Lassa viral fever belong to the areas of Liberia and Sierra Leone.
- Key pharmaceutical companies of the Lassa virus market are focused on research and development activities regarding the development of vaccines and diagnostic tests for the Lassa virus.
- Promising growth in revenue in the Lassa virus market is expected during the forecast period, as various key players of the market are set to launch novel Lassa viral fever treatment products.
- West Africa dominates the Lassa virus market, due to the presence of large patient pool prone to get infected with the virus and the increasing incidence of the disease in people from all age groups in the Middle East and Africa.
Key Benefits of the Report
- This study presents the analytical depiction of the Lassa virus industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the Lassa virus market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
- Questions Answered in the Lassa Virus Report
- Which are the leading players active in the Lassa virus market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the Lassa virus in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps in the market?
- What are the impacts of COVID-19 on the industry?
- What is the Lassa virus?
- What are the current and predicted trends of the market?
Lassa Virus Market Report Highlights
| Aspects | Details |
 By Treatment |
|
 By Diagnosis |
|
 By End User |
|
 By Region |
|
 Key Market Players | F. Hoffmann La Roche AG, Valeant pharmaceuticals international, Teva Pharmaceuticals, Zydus Pharmaceuticals, Sandoz Inc. (Novartis AG), Schering-Plough Research Institute, Three Rivers Pharmaceuticals LLC |
Loading Table Of Content...
